Metabolic bone disease in cirrhosis patients

Long-standing liver disease has long been recognized to result in fragile bones with increased risk of fractures. In various international studies, the overall incidence has varied from 11% to 48%, with a fracture rate of 3%-44%.

However, the reason for this is poorly understood. With liver transplantation becoming a viable option in liver disease and offering complete cure and long-term survival, bone disease is becoming the major determinant of survival and quality of life in these patients.

A research article to be published on July 28, 2009 in the World Journal of Gastroenterology addresses this question. This research team was led by Tushar R Bandgar from KEM Hospital, India.

They found that low bone formation and increased resorption led to fragile bones in these patients. Contributing factors identified were inadequate sunlight exposure, reduced physical activity, low body weight, vitamin D deficiency and low level of testosterone. They also demonstrated that the severity of bone loss was accelerated in patients with low IGF-1 level. IGF-1 is normally synthesized in the liver and its synthesis is affected early in cirrhosis. The present study also found that the increased estrogen level seen in cirrhosis was protective against osteopenia.

These results shed new light on bone disorders seen in patients with cirrhosis. As most of the factors identified are correctable or treatable, it should provide additional help in treatment of these patients, such that they have better quality of life and survival.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New insights into survival of breast cancer cells in the bone marrow